Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.

T-cell defects, immune suppression, and poor antitumor immune responses are hallmarks of chronic lymphocytic leukemia (CLL), and PD-1/PD-L1 inhibitory signaling has emerged as a major immunosuppressive mechanism. However, the effect of different microenvironments and the confounding influence of aging are poorly understood. The current study uses the Eμ-TCL1 mouse model, which replicates human T-cell defects, as a preclinical platform to longitudinally examine patterns of T-cell dysfunction alongside developing CLL and in different microenvironments, with a focus on PD-1/PD-L1 interactions. The development of CLL was significantly associated with changes in T-cell phenotype across all organs and function. Although partly mirrored in aging wild-type mice, CLL-specific T-cell changes were identified. Murine CLL cells highly expressed PD-L1 and PD-L2 in all organs, with high PD-L1 expression in the spleen. CD3(+)CD8(+) T cells from leukemic and aging healthy mice highly expressed PD-1, identifying aging as a confounder, but adoptive transfer experiments demonstrated CLL-specific PD-1 induction. Direct comparisons of PD-1 expression and function between aging CLL mice and controls identified PD-1(+) T cells in CLL as a heterogeneous population with variable effector function. This is highly relevant for therapeutic targeting of CD8(+) T cells, showing the potential of reprogramming and selective subset expansion to restore antitumor immunity.

[1]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[2]  C. Horn,et al.  Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T‐cells in chronic lymphocytic leukemia , 2014, International journal of cancer.

[3]  John T. Chang,et al.  Molecular regulation of effector and memory T cell differentiation , 2014, Nature Immunology.

[4]  G. Lenz,et al.  Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation. , 2014, Cancer discovery.

[5]  J. Nikolich-Žugich,et al.  Aging of the T Cell Compartment in Mice and Humans: From No Naive Expectations to Foggy Memories , 2014, The Journal of Immunology.

[6]  U. Klein,et al.  Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy. , 2014, Blood.

[7]  D. Weisenburger,et al.  Chronic Lymphocytic Leukemia Cells in a Lymph Node Microenvironment Depict Molecular Signature Associated with an Aggressive Disease , 2014, Molecular medicine.

[8]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[9]  C. Croce,et al.  Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia , 2014, Leukemia.

[10]  J. Gribben,et al.  The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. , 2014, Seminars in cancer biology.

[11]  E. Remmerswaal,et al.  CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia. , 2014, Blood.

[12]  H. Pircher,et al.  Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype , 2013, Cancer Immunology, Immunotherapy.

[13]  Keith M. Thompson,et al.  Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. , 2013, Cell reports.

[14]  A. Legat,et al.  T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion , 2013, Nature Immunology.

[15]  Michael Loran Dustin,et al.  PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis , 2013, The Journal of experimental medicine.

[16]  J. Gribben,et al.  Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. , 2013, Blood.

[17]  J. Gribben,et al.  Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications. , 2013, Hematology/oncology clinics of North America.

[18]  J. Gribben,et al.  T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. , 2013, Blood.

[19]  D. Rossi,et al.  The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia , 2012, Haematologica.

[20]  W. Wilson,et al.  Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. , 2012, Blood.

[21]  J. Gribben,et al.  Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. , 2012, Blood.

[22]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[23]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[24]  Takashi Saito,et al.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 , 2012, The Journal of experimental medicine.

[25]  Peter Vogel,et al.  Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape , 2022 .

[26]  C. Fegan,et al.  Expansion of a CD8+PD-1+ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD4:CD8 Ratios and Disease Progression , 2011, Clinical Cancer Research.

[27]  E. Wherry T cell exhaustion , 2011, Nature Immunology.

[28]  R. Greil,et al.  Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL , 2011, Leukemia.

[29]  Annette Lee,et al.  A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. , 2011, Blood.

[30]  Michael J. Zilliox,et al.  Phenotype, Function, and Gene Expression Profiles of Programmed Death-1hi CD8 T Cells in Healthy Human Adults , 2011, The Journal of Immunology.

[31]  Steven J. M. Jones,et al.  MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers , 2011, Nature.

[32]  Richard Sherry,et al.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. , 2011, Blood.

[33]  Antonio Polley,et al.  Tissue-Specific Differences in PD-1 and PD-L1 Expression during Chronic Viral Infection: Implications for CD8 T-Cell Exhaustion , 2009, Journal of Virology.

[34]  John Quackenbush,et al.  Eμ-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction , 2009, Proceedings of the National Academy of Sciences.

[35]  G. Freeman,et al.  Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade , 2008, Proceedings of the National Academy of Sciences.

[36]  J. Byrd,et al.  Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. , 2008, The Journal of clinical investigation.

[37]  Marcos González,et al.  Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients. , 2008, Blood.

[38]  J. Salisbury,et al.  CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. , 2008, Blood.

[39]  M. Azuma,et al.  Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer , 2007, Clinical Cancer Research.

[40]  Yoshimasa Tanaka,et al.  Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[41]  Annelieke Jaspers,et al.  Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. , 2007, Blood.

[42]  R. Koup,et al.  PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection , 2006, The Journal of experimental medicine.

[43]  Philip J. R. Goulder,et al.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.

[44]  J. Gribben,et al.  Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. , 2005, The Journal of clinical investigation.

[45]  M. Azuma,et al.  Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer , 2005, Clinical Cancer Research.

[46]  R. Koup,et al.  Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. , 2003, Journal of immunological methods.

[47]  C. Croce,et al.  Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[48]  M. Chilosi,et al.  Chronic B cell malignancies and bone marrow microenvironment. , 2002, Seminars in cancer biology.

[49]  Michael F Denny,et al.  Superantigen-Induced T Cell:B Cell Conjugation Is Mediated by LFA-1 and Requires Signaling Through Lck, But Not ZAP-701 , 2001, The Journal of Immunology.

[50]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[51]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[52]  T. Honjo,et al.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. , 1999, Immunity.

[53]  B. Clarkson,et al.  Abnormal T lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia: an analysis by monoclonal antibodies. , 1982, Journal of immunology.

[54]  F. Herrmann,et al.  Imbalance of T cell subpopulations in patients with chronic lymphocytic leukaemia of the B cell type. , 1982, Clinical and experimental immunology.

[55]  D. Catovsky,et al.  Clinical significance of T-cells in chronic lymphocytic leukaemia. , 1974, Lancet.

[56]  Antonio Polley,et al.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection , 2009, Nature Immunology.

[57]  A. Philippon,et al.  REFERENCES CONTENT ALERTS Updated information and services can be found at: , 1999 .